Identification of microRNA which regulates peritoneal dissemination of ovarian cancer

卵巢癌是一种以广泛的腹膜播散和腹水为特征的高度转移性肿瘤，是妇科恶性肿瘤死亡的主要原因。我们以前已经确定整合素α5作为卵巢癌治疗的一个新靶点，通过抑制腹膜播散。我们的目的是鉴定新的调控整合素α5表达的microRNA，并分析靶向其microRNA的治疗潜力。基于microRNA算法搜索，我们将hsa-mir-92 a鉴定为候选者。Hsa-mir-92 a在高水平表达整合素α5的卵巢癌细胞中几乎不表达，而hsa-mir-92 a在不表达整合素α5的RMUG-S细胞中高表达。转染前体mir-92 a可降低卵巢癌细胞中整合素α5的表达，同时抑制细胞粘附和侵袭。这些结果表明，靶向hsa-mir-92 a通过抑制整合素α5表达，可能是一种有希望的治疗卵巢癌患者的方法。

Ovarian cancer is a highly metastatic characterized by widespread peritoneal dissemination and ascites, and is the leading cause of death from gynecological malignancy. We have previously identified integrinα5 as a new target in ovarian cancer treatment by inhibiting peritoneal dissemination. Our aim is to identify new microRNA which regulates the expression of integrinα5 and analyze the therapeutic potential of targeting of its microRNA. Based on the microRNA algorism search, we identified hsa-mir-92a as a candidate. Hsa-mir-92a is little expressed in ovarian cancer cells which express high level of integrinα5, whereas hsa-mir-92a is highly expressed in RMUG-S cells which do not express integrinα5. Transfection of precursor mir-92a reduced integrinα5 expression in ovarian cancer cells, accompanied by the inhibition of cell adhesion and invasion. Those results suggested targeting hsa-mir-92a could be a promising therapy for a subset of ovarian cancer patients by inhibiting integrin α5 expression.